The publication of modern slavery statements (statements) on this Register does not indicate compliance with the requirements of the Modern Slavery Act 2018 (the Act). Pursuant to section 19(2) of the Act, the Attorney-General’s Department publishes all statements properly submitted to this Register, including compliant and non-compliant statements, in order to maximise transparency and ensure entities are publicly accountable for their actions to address modern slavery risks. Statements that fail to meet the requirements for approval and signature set out in sections 13(2) or 14(2) of the Act will not be registered.

Number
2022-1206
Type
Joint
Title
iNova Pharmaceuticals Group 2021
Period
01 January 2021 to 31 December 2021
Annual revenue
150-200M
Industry sectors
Healthcare and pharmaceuticals
Countries
Singapore
Key brands and business names
Difflam, Duro-Tuss, Demazin, DermaVeen, Invisible Zinc
Date submitted
30/06/2022
Date published
18/08/2022